Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Efficacy of Cefditoren Pivoxil for Exacerbation of Chronic Obstructive Pulmonary Disease

Trial Profile

Clinical Efficacy of Cefditoren Pivoxil for Exacerbation of Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cefditoren pivoxil (Primary)
  • Indications Bacterial infections; Chronic obstructive pulmonary disease; Respiratory tract infections
  • Focus Therapeutic Use

Most Recent Events

  • 09 Jul 2019 Status changed from active, no longer recruiting to completed.
  • 23 May 2017 Status changed from recruiting to active, no longer recruiting.
  • 27 Feb 2015 Planned End Date changed from 31 Jul 2014 to 30 Apr 2017 as per University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top